Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR)*

por Kimball, AB, Leonardi, C, Stahle, M, Gulliver, W, Chevrier, M, Fakharzadeh, S, Goyal, K, Calabro, S, Langholff, W, Menter, A
Publicado 2014

Real‐world effectiveness of adalimumab in patients with moderate‐to‐severe hidradenitis suppurativa: the 1‐year SOLACE study

por Gulliver, W., Alavi, A., Wiseman, M.C., Gooderham, M.J., Rao, J., Alam, M.S., Papp, K.A., Desjardins, O., Jean, C.
Publicado 2021

Adalimumab medium‐term dosing strategy in moderate‐to‐severe hidradenitis suppurativa: integrated results from the phase III randomized placebo‐controlled PIONEER trials

por Jemec, G.B.E., Okun, M.M., Forman, S.B., Gulliver, W.P.F., Prens, E.P., Mrowietz, U., Armstrong, A.W., Geng, Z., Gu, Y., Williams, D.A., Teixeira, H.D., Kimball, A.B.
Publicado 2019

Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization – systematic review and recommendations from the HS ALLIANCE working group

por Zouboulis, C.C., Bechara, F.G., Dickinson‐Blok, J.L., Gulliver, W., Horváth, B., Hughes, R., Kimball, A.B., Kirby, B., Martorell, A., Podda, M., Prens, E.P., Ring, H.C., Tzellos, T., van der Zee, H.H., van Straalen, K.R., Vossen, A.R.J.V., Jemec, G.B.E.
Publicado 2018